LABFF (Laboratorios Farmaceuticos Rovi) Net Income From Continuing Operations: $201.8 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LABFF Laboratorios Farmaceuticos Rovi SA LABFF
89 GF Score
Price $90.61
GF Value $86.21
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Net Income From Continuing Operations?

Laboratorios Farmaceuticos Rovi LABFF 89 Net Income From Continuing Operations is $201.8 Mil as of Mar. 2026. GuruFocus rates LABFF with a GF Score™ of 89/100 and a GF Value™ of $86.21. The stock has 1 warning sign investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Laboratorios Farmaceuticos Rovi's net income from continuing operations for the three months ended in Mar. 2026 was $14.2 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2026 was $201.8 Mil.

Laboratorios Farmaceuticos Rovi Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Net Income From Continuing Operations Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 206.36 273.27 240.36 186.06 214.59

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.70 30.89 88.85 67.85 14.21
LABFF
89GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $201.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $201.8 Mil mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Net Income From Continuing Operations of $201.8 Mil as of Mar. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Net Income From Continuing Operations too high?
Laboratorios Farmaceuticos Rovi's current Net Income From Continuing Operations is $201.8 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Net Income From Continuing Operations compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Net Income From Continuing Operations of $201.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Drug Manufacturers company?
A good Net Income From Continuing Operations depends on the Drug Manufacturers industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Net Income From Continuing Operations is $201.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Net Income From Continuing Operations of $201.8 Mil. The stock's GF Value™ is $86.21, compared to a current price of $90.61 — trading 5.1% above its estimated fair value. The current Net Income From Continuing Operations is $201.8 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Net Income From Continuing Operations is $201.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of $90.61 is trading 5.1% above its estimated GF Value™ of $86.21.

Key valuation signals for LABFF:

  • Net Income From Continuing Operations: $201.8 Mil
  • GF Value™: $86.21 vs. price of $90.61 (5.1% above fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score

Get the complete analysis for LABFF

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.61
Price
$86.21
GF Value